Etiology of Persistent Microalbuminuria in Nigeria (P_MICRO study): protocol and study design

[1]  N. Powe,et al.  New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race. , 2021, The New England journal of medicine.

[2]  H. Salihu,et al.  The Burden of HIV, Hepatitis B and Hepatitis C by Armed Conflict Setting: The Nigeria AIDS Indicator and Impact Survey, 2018 , 2021, Annals of global health.

[3]  M. Balcells-Oliveró,et al.  Validation of the Alcohol Smoking and Substance Involvement Screening Test (ASSIST) in acute psychiatric inpatients. , 2021, Adicciones.

[4]  P. Kimmel,et al.  Apolipoprotein-1 risk variants and associated kidney phenotypes in an adult HIV cohort in Nigeria. , 2021, Kidney international.

[5]  Y. Ilan,et al.  Hepatitis A and Other Viral Infections , 2020, Liver Immunology.

[6]  C. Tremblay,et al.  Cytomegalovirus Seropositivity Is Associated With Increased Microbial Translocation in People Living With Human Immunodeficiency Virus and Uninfected Controls , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  P. Kimmel,et al.  Optimal management of HIV- positive adults at risk for kidney disease in Nigeria (Renal Risk Reduction “R3” Trial): protocol and study design , 2019, Trials.

[8]  M. Sarwal,et al.  A Novel Multi-Biomarker Assay for Non-Invasive Quantitative Monitoring of Kidney Injury , 2019, Journal of clinical medicine.

[9]  N. Prasad,et al.  Infection-Induced Kidney Diseases , 2018, Front. Med..

[10]  K. Polman,et al.  Intestinal parasites: Associations with intestinal and systemic inflammation , 2018, Parasite immunology.

[11]  F. Harrell,et al.  Modeling continuous response variables using ordinal regression , 2017, Statistics in medicine.

[12]  T. Rossouw,et al.  HIV as a Cause of Immune Activation and Immunosenescence , 2017, Mediators of inflammation.

[13]  W. Kupin.  Viral-Associated GN: Hepatitis B and Other Viral Infections. , 2017, Clinical journal of the American Society of Nephrology : CJASN.

[14]  D. Cohen,et al.  Publisher's Note , 2017, Neuroscience & Biobehavioral Reviews.

[15]  S. Reed,et al.  The Severity of Visceral Leishmaniasis Correlates with Elevated Levels of Serum IL-6, IL-27 and sCD14 , 2016, PLoS neglected tropical diseases.

[16]  M. Ramsay,et al.  APOL1 Risk Variants Are Strongly Associated with HIV-Associated Nephropathy in Black South Africans. , 2015, Journal of the American Society of Nephrology : JASN.

[17]  Patrick D. Dummer,et al.  APOL1 Toxin, Innate Immunity and Kidney Injury , 2015, Kidney international.

[18]  A. Reiner,et al.  Association of sickle cell trait with chronic kidney disease and albuminuria in African Americans. , 2014, JAMA.

[19]  M. Lederman,et al.  Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment. , 2014, The Journal of infectious diseases.

[20]  Sanjiv J. Shah,et al.  Association of Low-Grade Albuminuria With Adverse Cardiac Mechanics: Findings From the Hypertension Genetic Epidemiology Network (HyperGEN) Study , 2014, Circulation.

[21]  Josef Coresh,et al.  Cystatin C versus creatinine in determining risk based on kidney function. , 2013, The New England journal of medicine.

[22]  A. McMahon,et al.  Chronic epithelial kidney injury molecule-1 expression causes murine kidney fibrosis. , 2013, The Journal of clinical investigation.

[23]  Liang Li,et al.  A Weighting Analogue to Pair Matching in Propensity Score Analysis , 2013, The international journal of biostatistics.

[24]  R. Barsoum.  Parasitic kidney disease: milestones in the evolution of our knowledge. , 2013, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[25]  M. Woodward,et al.  Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis , 2012, The Lancet.

[26]  C. Sabin,et al.  Simultaneous measurement of urinary albumin and total protein may facilitate decision‐making in HIV‐infected patients with proteinuria , 2012, HIV medicine.

[27]  L. Kuller,et al.  Inflammation, Coagulation and Cardiovascular Disease in HIV-Infected Individuals , 2012, PloS one.

[28]  D. Costagliola,et al.  HIV replication and immune status are independent predictors of the risk of myocardial infarction in HIV-infected individuals. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[29]  K. Kraemer,et al.  HIV status, burden of comorbid disease, and biomarkers of inflammation, altered coagulation, and monocyte activation. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[30]  Peter W. Hunt,et al.  HIV and Inflammation: Mechanisms and Consequences , 2012, Current HIV/AIDS Reports.

[31]  G. Genovese,et al.  APOL1 and kidney disease , 2012, Current opinion in nephrology and hypertension.

[32]  M. Hulihan,et al.  Public health implications of sickle cell trait: a report of the CDC meeting. , 2011, American journal of preventive medicine.

[33]  Jeffrey N. Martin,et al.  Impact of CD8+ T-cell activation on CD4+ T-cell recovery and mortality in HIV-infected Ugandans initiating antiretroviral therapy , 2011, AIDS.

[34]  Giulio Genovese,et al.  APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. , 2011, Journal of the American Society of Nephrology : JASN.

[35]  A. Köttgen,et al.  Trefoil Factor 3 Predicts Incident Chronic Kidney Disease: A Case-Control Study Nested within the Atherosclerosis Risk in Communities (ARIC) Study , 2011, American Journal of Nephrology.

[36]  S. Lawson-Ayayi,et al.  Increased risk of abnormal proximal renal tubular function with HIV infection and antiretroviral therapy. , 2011, Kidney international.

[37]  S. Roberts,et al.  Prediction of pre‐eclampsia in early pregnancy by estimating the spot urinary albumin: creatinine ratio using high‐performance liquid chromatography , 2011, BJOG : an international journal of obstetrics and gynaecology.

[38]  D. Boulware,et al.  Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death. , 2011, The Journal of infectious diseases.

[39]  S. Lewin,et al.  Plasma levels of soluble CD14 independently predict mortality in HIV infection. , 2011, The Journal of infectious diseases.

[40]  A. Sharrett,et al.  T Cell Activation and Senescence Predict Subclinical Carotid Artery Disease in HIV-Infected Women , 2011, The Journal of infectious diseases.

[41]  N. Key,et al.  Sickle-cell trait: novel clinical significance. , 2010, Hematology. American Society of Hematology. Education Program.

[42]  L. Szczech,et al.  Cystatin C, albuminuria, and 5-year all-cause mortality in HIV-infected persons. , 2010, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[43]  A. Zolopa,et al.  Inflammation and Mortality in HIV-Infected Adults: Analysis of the FRAM Study Cohort , 2010, Journal of acquired immune deficiency syndromes.

[44]  Xiao-mei Li,et al.  Pathological significance of a panel of urinary biomarkers in patients with drug-induced tubulointerstitial nephritis. , 2010, Clinical journal of the American Society of Nephrology : CJASN.

[45]  C. Winkler,et al.  The apolipoprotein L1 (APOL1) gene and nondiabetic nephropathy in African Americans. , 2010, Journal of the American Society of Nephrology : JASN.

[46]  Mardge H. Cohen,et al.  Microalbuminuria Is Associated With All-Cause and AIDS Mortality in Women With HIV Infection , 2010, Journal of acquired immune deficiency syndromes.

[47]  C. Winkler,et al.  Association of Trypanolytic ApoL1 Variants with Kidney Disease in African Americans , 2010, Science.

[48]  D. Costagliola,et al.  Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4. , 2010, Archives of internal medicine.

[49]  G. Werneck,et al.  Is severe visceral leishmaniasis a systemic inflammatory response syndrome? A case control study. , 2010, Revista da Sociedade Brasileira de Medicina Tropical.

[50]  D. Jacobs,et al.  Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. , 2010, The Journal of infectious diseases.

[51]  M. Woodward,et al.  Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis , 2010, The Lancet.

[52]  D. Costagliola,et al.  No evidence for a polyomavirus association or aetiology in AIDS-associated nonsmall cell lung cancer , 2010, AIDS.

[53]  D. Gerhold,et al.  Kidney Injury Molecule-1 Outperforms Traditional Biomarkers of Kidney Injury in Multi-site Preclinical Biomarker Qualification Studies , 2010, Nature Biotechnology.

[54]  A. Kshirsagar,et al.  High prevalence of sickle cell trait in African Americans with ESRD. , 2010, Journal of the American Society of Nephrology : JASN.

[55]  C. Winkler,et al.  Genetics of focal segmental glomerulosclerosis and human immunodeficiency virus-associated collapsing glomerulopathy: the role of MYH9 genetic variation. , 2010, Seminars in nephrology.

[56]  H. Goto,et al.  Immunoactivation and immunopathogeny during active visceral leishmaniasis. , 2009, Revista do Instituto de Medicina Tropical de Sao Paulo.

[57]  M. King,et al.  Serum immune activation markers are persistently increased in patients with HIV infection after 6 years of antiretroviral therapy despite suppression of viral replication and reconstitution of CD4+ T cells. , 2009, The Journal of infectious diseases.

[58]  A. Justice,et al.  Incidence of Non-AIDS-Defining Malignancies in HIV-Infected Versus Noninfected Patients in the HAART Era: Impact of Immunosuppression , 2009, Journal of acquired immune deficiency syndromes.

[59]  A. Copas,et al.  Tenofovir‐associated renal and bone toxicity , 2009, HIV medicine.

[60]  G. Robbins,et al.  Proteinuria, creatinine clearance, and immune activation in antiretroviral-naive HIV-infected subjects. , 2009, The Journal of infectious diseases.

[61]  Y. Amoateng-Adjepong,et al.  Complications associated with sickle cell trait: a brief narrative review. , 2009, The American journal of medicine.

[62]  Lewis H Kuller,et al.  Inflammatory and Coagulation Biomarkers and Mortality in Patients with HIV Infection , 2008, PLoS medicine.

[63]  Ross J. Harris,et al.  Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies , 2008, The Lancet.

[64]  P. Sullivan,et al.  Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. , 2008, Annals of internal medicine.

[65]  Samir K. Gupta.  Tenofovir-associated Fanconi syndrome: review of the FDA adverse event reporting system. , 2008, AIDS patient care and STDs.

[66]  E. Eichner,et al.  Sickle cell trait. , 2007, Journal of sport rehabilitation.

[67]  B. Gazzard,et al.  The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years , 2007, AIDS.

[68]  A. Mocroft,et al.  Chronic renal failure among HIV-1-infected patients , 2007, AIDS.

[69]  A. Órfão,et al.  Abnormal cytokine production by circulating monocytes and dendritic cells of myeloid origin in ART-treated HIV-1+ patients relates to CD4+ T-cell recovery and HCV co-infection. , 2007, Current HIV research.

[70]  M. King,et al.  Evidence of ongoing immune reconstitution in subjects with sustained viral suppression following 6 years of lopinavir-ritonavir treatment. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[71]  B. Gazzard,et al.  Tenofovir Disoproxil Fumarate, Emtricitabine, and Efavirenz Versus Fixed-Dose Zidovudine/Lamivudine and Efavirenz in Antiretroviral-Naive Patients: Virologic, Immunologic, and Morphologic Changes-A 96-Week Analysis , 2006, Journal of acquired immune deficiency syndromes.

[72]  B. Gazzard.  British HIV Association guidelines for the treatment of HIV‐1‐infected adults with antiretroviral therapy 2008 , 2005, HIV medicine.

[73]  D. Siscovick,et al.  Cystatin C and the risk of death and cardiovascular events among elderly persons. , 2005, The New England journal of medicine.

[74]  Qing Ma,et al.  Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery , 2005, The Lancet.

[75]  G. Leroux-Roels,et al.  Hepatitis B virus and human immunodeficiency virus co‐infection in sub‐Saharan Africa: a call for further investigation , 2005, Liver international : official journal of the International Association for the Study of the Liver.

[76]  A. Órfão,et al.  Different subsets of peripheral blood dendritic cells show distinct phenotypic and functional abnormalities in HIV-1 infection , 2005, AIDS.

[77]  H. Gerstein,et al.  Albuminuria as a predictor of cardiovascular and renal outcomes in people with known atherosclerotic cardiovascular disease. , 2004, Kidney international. Supplement.

[78]  Joel E Gallant,et al.  Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. , 2004, JAMA.

[79]  I. Clark,et al.  Pathogenesis of Malaria and Clinically Similar Conditions , 2004, Clinical Microbiology Reviews.

[80]  J. Reynes,et al.  Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases. , 2004, Journal of acquired immune deficiency syndromes.

[81]  Jeffrey N. Martin,et al.  T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. , 2003, The Journal of infectious diseases.

[82]  F. Locatelli,et al.  The importance of early detection of chronic kidney disease. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[83]  S. Sidney,et al.  Do Protease Inhibitors Increase the Risk for Coronary Heart Disease in Patients With HIV‐1 Infection? , 2002, Journal of acquired immune deficiency syndromes.

[84]  J. Bonventre,et al.  Kidney Injury Molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. , 2002, Kidney international.

[85]  R. Spitzer,et al.  The PHQ-9 , 2001, Journal of General Internal Medicine.

[86]  S. Yusuf,et al.  Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. , 2001, JAMA.

[87]  M. V. van Velthuysen,et al.  Glomerulopathy Associated with Parasitic Infections , 2000, Clinical Microbiology Reviews.

[88]  W E Barlow,et al.  Analysis of case-cohort designs. , 1999, Journal of clinical epidemiology.

[89]  G. Eknoyan,et al.  Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): a position paper of the National Kidney Foundation. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[90]  J V Giorgi,et al.  Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. , 1999, The Journal of infectious diseases.

[91]  R. Detels,et al.  Prognostic significance of plasma markers of immune activation, HIV viral load and CD4 T‐cell measurements , 1998, AIDS.

[92]  R. Detels,et al.  CD8+ T-lymphocyte activation in HIV-1 disease reflects an aspect of pathogenesis distinct from viral burden and immunodeficiency. , 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[93]  P. Winocour,et al.  Microalbuminuria. , 1992 .

[94]  R. Badaró,et al.  Tumor necrosis factor (cachectin) in human visceral leishmaniasis. , 1991, The Journal of infectious diseases.

[95]  J M Taylor,et al.  The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. , 1990, The New England journal of medicine.

[96]  D. Kumar,et al.  Calcium/creatinine ratio and microalbuminuria in the prediction of preeclampsia. , 1988, American journal of obstetrics and gynecology.

[97]  M. Yamanaka,et al.  Urinary protein as measured with a pyrogallol red-molybdate complex, manually and in a Hitachi 726 automated analyzer. , 1986, Clinical chemistry.

[98]  W. Best,et al.  Clinical implications of sickle-cell trait and glucose-6-phosphate dehydrogenase deficiency in hospitalized black male patients. , 1979, The New England journal of medicine.

[99]  H. Bartels,et al.  [Micro-determination of creatinine]. , 1971, Clinica chimica acta; international journal of clinical chemistry.

[100]  L. W. Statius van Eps,et al.  Nature of concentrating defect in sickle-cell nephropathy. Microradioangiographic studies. , 1970, Lancet.

[101]  B. Maegraith.  Pathological processes in malaria. , 1948, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[102]  J. Böhnke.  Explanation in causal inference: Methods for mediation and interaction. , 2016, Quarterly journal of experimental psychology.

[103]  B. Astor,et al.  Risk of incident ESRD: a comprehensive look at cardiovascular risk factors and 17 years of follow-up in the Atherosclerosis Risk in Communities (ARIC) Study. , 2010, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[104]  R. Spitzer,et al.  The PHQ-9: validity of a brief depression severity measure. , 2001, Journal of general internal medicine.